Oarsman Capital Inc. Has $221,000 Holdings in GSK plc (NYSE:GSK)

Oarsman Capital Inc. boosted its stake in GSK plc (NYSE:GSK) by 28.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,528 shares of the pharmaceutical company’s stock after purchasing an additional 1,450 shares during the period. Oarsman Capital Inc.’s holdings in GSK were worth $221,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. Primecap Management Co. CA raised its position in shares of GSK by 70.1% during the fourth quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company’s stock worth $854,349,000 after acquiring an additional 10,407,905 shares during the last quarter. Fisher Asset Management LLC lifted its position in shares of GSK by 1.4% in the 4th quarter. Fisher Asset Management LLC now owns 18,836,797 shares of the pharmaceutical company’s stock worth $637,061,000 after purchasing an additional 259,867 shares during the period. Mondrian Investment Partners LTD boosted its stake in shares of GSK by 17.6% in the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company’s stock valued at $205,920,000 after purchasing an additional 874,004 shares during the last quarter. Equity Investment Corp increased its position in shares of GSK by 13.3% during the fourth quarter. Equity Investment Corp now owns 3,962,581 shares of the pharmaceutical company’s stock worth $134,014,000 after buying an additional 466,327 shares during the period. Finally, Wellington Management Group LLP raised its stake in GSK by 10.0% during the fourth quarter. Wellington Management Group LLP now owns 2,094,105 shares of the pharmaceutical company’s stock worth $70,823,000 after buying an additional 190,047 shares during the last quarter. 15.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on GSK. Morgan Stanley started coverage on shares of GSK in a research report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com upgraded GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Seven research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Trading Down 6.5 %

Shares of GSK stock opened at $36.49 on Friday. The stock has a market capitalization of $75.53 billion, a PE ratio of 22.95, a price-to-earnings-growth ratio of 1.12 and a beta of 0.56. GSK plc has a 52 week low of $31.72 and a 52 week high of $45.93. The stock has a 50 day moving average price of $37.63 and a two-hundred day moving average price of $36.55. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.52 and a current ratio of 0.78.

GSK (NYSE:GSK) last released its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, topping the consensus estimate of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. As a group, equities analysts anticipate that GSK plc will post 4.14 earnings per share for the current fiscal year.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be given a dividend of $0.3932 per share. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. This represents a $1.57 annualized dividend and a dividend yield of 4.31%. GSK’s payout ratio is presently 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.